Pharma & Biotech VC & Investment News
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Today's issue
Refine Search
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, has closed a $215 million Series B financing to further advance its portfolio of clinical-stage, nutrient-stimulated hormone (NuSH) analog peptides. 14 November 2024
Pharmaceutical
Life science investor Syncona has announced the launch of its newest portfolio company, Slingshot Therapeutics, through the Syncona Accelerator initiative. 14 November 2024
Biotechnology
Danish life sciences investor Novo Holdings is continuing the spread of its cash pile, this time as co-leader of a $181.4 million Series D financing in Alentis Therapeutics. 12 November 2024
Biotechnology
Trace Neuroscience, a newly launched biopharma based in San Francisco, aims to advance treatments for neurodegenerative diseases, starting with amyotrophic lateral sclerosis (ALS). 12 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Biotechnology
US biotech venture fund Aditum Bio and China’s Leads Biolabs today announced the formation of Oblenio Bio, marking the thirteenth company launched by Aditum. 7 November 2024
Pharmaceutical
PrognomiQ has announced a series D financing round of $34 million, led by Seer, bringing the firm’s total funding to over $135 million since its founding in September 2020. 6 November 2024
Pharmaceutical
Syndax Pharmaceuticals has entered into a $350 million royalty funding agreement with Royalty Pharma. 6 November 2024
Biotechnology
A new Seattle-based biotech company has the best endorsement imaginable as it emerges from stealth. Archon Biosciences’ platform, leveraging AI-driven advances in computational protein design, were recognized earlier this month by the awarding of the 2024 Nobel Prize in Chemistry, for its ability to create novel proteins with desired functions. 31 October 2024
Biotechnology
Boston, USA-based biotech Axonis Therapeutics, which is focused on the development of novel neuromedicines, has announced the successful completion of an oversubscribed $115 million Series A financing. 31 October 2024
Pharmaceutical
Oxford, UK-based Blue Earth Therapeutics, an emerging leader in the development of therapeutic radiopharmaceuticals, today announces completion of a $76.5 million Series A financing. 30 October 2024
Biotechnology
San Francisco, USA-based biotech start-up Kivu Bioscience has announced the closing of a $92 million Series A financing round led by Novo Holdings, which as of year-end 2011123 had total assets of 149 billion euros ($161 billion). 28 October 2024
Biotechnology
Ottimo Pharma, a biotech founded by Medicxi in 2020, has emerged from stealth mode with an executive team packed with prominent industry leaders. 28 October 2024
Biotechnology
Biostar Pharmaceuticals has announced its upcoming initial public offering (IPO) on the Hong Kong Stock Exchange, aiming to raise funds to advance its growing oncology pipeline and support its global expansion efforts. 25 October 2024
Pharmaceutical
Madrigal Pharmaceuticals saw its shares close down 6.2% at $265.68 yesterday, after it announced the pricing of its underwritten public offering of 750,000 shares of its common stock. 20 March 2024
Biotechnology
San-Diego Contineum Therapeutics, biotech developing small molecule therapies for the treatment of neuroscience, inflammation, and immunology (NI&I) indications, is going public. 19 March 2024
Biotechnology
Samsung Life Science Fund announced Samsung’s investment in Boston, USA-based BrickBio, a pre-clinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. 19 March 2024
Pharmaceutical
In the UK, research originating from Cambridge University has received a significant vote of confidence from investors banking on the therapeutic potential of mitochondria. 18 March 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
New York-based neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA). 14 March 2024
Biotechnology
German antibody drug conjugate (ADC) specialist Tubulis has announced the successful completion of an upsized and oversubscribed 128 million euros ($138.8 million) Series B2 financing. 14 March 2024
Biotechnology
New research undertaken by IQVIA shows that cell and gene therapies have received unprecedented amounts of funding in recent years. 14 March 2024
Pharmaceutical
A private share placement should see Regulus Therapeutics swell its coffers by around $100 million. 13 March 2024
Biotechnology
The biopharmaceutical industry is witnessing a shift in investor sentiment. Despite facing challenges such as declining venture financing and macroeconomic pressures, there exists optimism about a recovery in biotech funding. 13 March 2024
Biotechnology
In a filing with the US Securities and Exchange Commission (SEC), Boundless Bio has revealed its intention for an initial public offering (IPO). 7 March 2024
Biotechnology
Israeli company BiomX has entered into a definitive merger agreement with Adaptive Phage Therapeutics, a USA-based, privately-held, biotech developing phage-based therapies to combat bacterial infections. 6 March 2024
Biotechnology
Today Boston, USA-based Sionna Therapeutics announced it closed a $182 million Series C financing, one of the largest late-stage rounds in biotech so far this year. 6 March 2024
Pharmaceutical
Nashville, USA-based biotech Revance Therapeutics has announced an underwritten public offering, with the goal of raising $100 million. 5 March 2024
Biotechnology
Belgian biotech UCB has made a strategic equity investment in a Californian immune system specialist, IMIDomics. 5 March 2024
Pharmaceutical
US biopharma Nocion Therapeutics has raised $62 million in Series B funding. 5 March 2024
Pharmaceutical
Cambridge, USA-based clinical-stage cancer drug developer FogPharma on Friday announced the successful closing of a $145 million Series E financing round. 2 March 2024
Pharmaceutical
San Diego-based BlossomHill Therapeutics, a company focused on the design and development of small molecules for cancer and autoimmune diseases, has announced the closing of a $100 million Series B financing round. 1 March 2024
Pharmaceutical
Fore Biotherapeutics, a precision oncology start-up founded in 2011, has selected William Hinshaw as its new chief executive. 29 February 2024
Biotechnology
Avidity Biosciences has announced an oversubscribed $400 million private placement, with the news sending the US RNA-focussed biotech firm’s shares up 21.8% to $18.58 by mid-morning. 29 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze